Cargando…
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
BACKGROUND AND OBJECTIVE: As new migraine prevention treatments are developed, the onset of a preventive effect, how long it is maintained and whether patients initially non-responsive develop clinically meaningful responses with continued treatment can be assessed. METHODS: Analyses were conducted...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691875/ https://www.ncbi.nlm.nih.gov/pubmed/31004075 http://dx.doi.org/10.1136/jnnp-2018-320242 |
_version_ | 1783443467978932224 |
---|---|
author | Goadsby, Peter J Dodick, David W Martinez, James M Ferguson, Margaret B Oakes, Tina M Zhang, Qi Skljarevski, Vladimir Aurora, Sheena K |
author_facet | Goadsby, Peter J Dodick, David W Martinez, James M Ferguson, Margaret B Oakes, Tina M Zhang, Qi Skljarevski, Vladimir Aurora, Sheena K |
author_sort | Goadsby, Peter J |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: As new migraine prevention treatments are developed, the onset of a preventive effect, how long it is maintained and whether patients initially non-responsive develop clinically meaningful responses with continued treatment can be assessed. METHODS: Analyses were conducted post-hoc of a double-blind, placebo-controlled, phase II-a study in patients with episodic migraine receiving galcanezumab 150 mg or placebo biweekly for 12 weeks (Lancet Neurol 13:885, 2014). The number of migraine headache days per week, and onset of efficacy measured as the first week galacanezumab separated from placebo were determined. Patients with ≥50%, ≥75% and 100% reduction in migraine headache days from baseline at months 1, 2 and 3 were calculated and defined as sustained responses. Non-responders (<50% response) at month 1 or 2 who then showed ≥50%, ≥75% and 100% response at later time-points were calculated. RESULTS: Patients were randomised to galcanezumab (n=107) or placebo (n=110). A significant (p=0.018) change of −0.89±0.11 (galcanezumab) vs −0.53±0.11 (placebo) migraine headache days indicated onset at week 1. Forty-seven per cent of galcanezumab and 25% of placebo patients responding at month 1 maintained response through months 2 and 3. Of non-responders at month 1, 27% on galcanezumab and 20% on placebo responded on months 2 and 3, and 50% of galcanezumab non-responders in months 1 and 2 responded on month 3, vs 24% on placebo. CONCLUSIONS: The onset of efficacy of galcanezumab is within 1 week in a majority of patients, and patients receiving galcanezumab are twice more likely to maintain responses than placebo patients. Early non-responders may respond by month 2 or month 3. TRIAL REGISTRATION NUMBER: NCT01625988. |
format | Online Article Text |
id | pubmed-6691875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-66918752019-08-26 Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis Goadsby, Peter J Dodick, David W Martinez, James M Ferguson, Margaret B Oakes, Tina M Zhang, Qi Skljarevski, Vladimir Aurora, Sheena K J Neurol Neurosurg Psychiatry Migraine BACKGROUND AND OBJECTIVE: As new migraine prevention treatments are developed, the onset of a preventive effect, how long it is maintained and whether patients initially non-responsive develop clinically meaningful responses with continued treatment can be assessed. METHODS: Analyses were conducted post-hoc of a double-blind, placebo-controlled, phase II-a study in patients with episodic migraine receiving galcanezumab 150 mg or placebo biweekly for 12 weeks (Lancet Neurol 13:885, 2014). The number of migraine headache days per week, and onset of efficacy measured as the first week galacanezumab separated from placebo were determined. Patients with ≥50%, ≥75% and 100% reduction in migraine headache days from baseline at months 1, 2 and 3 were calculated and defined as sustained responses. Non-responders (<50% response) at month 1 or 2 who then showed ≥50%, ≥75% and 100% response at later time-points were calculated. RESULTS: Patients were randomised to galcanezumab (n=107) or placebo (n=110). A significant (p=0.018) change of −0.89±0.11 (galcanezumab) vs −0.53±0.11 (placebo) migraine headache days indicated onset at week 1. Forty-seven per cent of galcanezumab and 25% of placebo patients responding at month 1 maintained response through months 2 and 3. Of non-responders at month 1, 27% on galcanezumab and 20% on placebo responded on months 2 and 3, and 50% of galcanezumab non-responders in months 1 and 2 responded on month 3, vs 24% on placebo. CONCLUSIONS: The onset of efficacy of galcanezumab is within 1 week in a majority of patients, and patients receiving galcanezumab are twice more likely to maintain responses than placebo patients. Early non-responders may respond by month 2 or month 3. TRIAL REGISTRATION NUMBER: NCT01625988. BMJ Publishing Group 2019-08 2019-04-19 /pmc/articles/PMC6691875/ /pubmed/31004075 http://dx.doi.org/10.1136/jnnp-2018-320242 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Migraine Goadsby, Peter J Dodick, David W Martinez, James M Ferguson, Margaret B Oakes, Tina M Zhang, Qi Skljarevski, Vladimir Aurora, Sheena K Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis |
title | Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis |
title_full | Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis |
title_fullStr | Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis |
title_full_unstemmed | Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis |
title_short | Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis |
title_sort | onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis |
topic | Migraine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691875/ https://www.ncbi.nlm.nih.gov/pubmed/31004075 http://dx.doi.org/10.1136/jnnp-2018-320242 |
work_keys_str_mv | AT goadsbypeterj onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis AT dodickdavidw onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis AT martinezjamesm onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis AT fergusonmargaretb onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis AT oakestinam onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis AT zhangqi onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis AT skljarevskivladimir onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis AT aurorasheenak onsetofefficacyanddurationofresponseofgalcanezumabforthepreventionofepisodicmigraineaposthocanalysis |